NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday that its board of directors has set the record and distribution dates for the spinoff of its wholly owned subsidiary, Myriad Pharmaceuticals.

The firm said that Myriad Genetics' shareholders of record on June 17 will receive on June 30 a pro-rata dividend of .25 share of Myriad Pharmaceuticals common stock for each share of Myriad Genetics held. Fractional shares will be paid in cash.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.